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Presentation of case
Dr. D. Schiller: During the preceding 4 weeks the
patient noticed progressive weakening in all four
extremities, first in the upper extremities and the
shoulder girdle and then in the lower extremities,
causing three falls during the 2 days before admission
on Easter Sunday, when tetraparesis was diagnosed
in the emergency room. On admission the patient
(height 161 cm, weight 71 kg) was alert, oriented and
afebrile. Muscle strength was graded 1–2 (grade 0 =
total paralysis, grade 5 = normal muscle contraction
against full resistance) in all four extremities. Sensory
function was normal in all extremities and cranial
nerve function was unremarkable. Blood pressure
was 180/100 mmHg with a regular pulse of 88 beats
per minute. The rest of the physical examination was
normal. The patient denied double vision, dysphagia
and dysarthria, myalgia, dysuria, dyschezia and re-
cent trauma (except for the three falls shortly before
admission), but she had experienced polyuria for the
last 2 years. Arterial hypertension had been diag-
nosed 4 years previously and treated with carvedilol
25 mg and ramipril/hydrochlorothiazide 5/25 mg q.d.
Electrocardiography showed sinus rhythm with nor-
mal P waves and QRS complexes but clearly flattened
T waves in the presence of U waves. Magnetic reso-
nance imaging (MRI) of the brain, the cervical spine
and the medulla was normal. Cerebrospinal fluid
analysis did not show pleocytosis or increased protein
concentration. Further laboratory results: normal red
and white blood cell counts except for neutrophilic
granulocytosis (16.8 g/l), sodium 144 mmol/l (nor-
mal: 132–145 mmol/l), potassium 1.5 mmol/l (nor-
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mal: 3.5–5.5 mmol/l), creatinine 0.9 mg/dl (normal:
0.5–0.9 mg/dl), aspartate aminotransferase (AST)
311 U/l (normal: 15–37 U/l), alanine aminotrans-
ferase (ALT) 121 U/l (normal: 12–34 U/l), creatine
kinase (CK) 11,788 U/l (normal: <145 U/l), plasmatic
coagulation parameters and markers of inflammation
were all within normal limits.
A panel of diagnostic tests was performed.
Differential diagnosis
Dr. A. Tomaschitz: When a patient presents with
tetraparesis, the physician might primarily suspect
a neurological cause or a neurodegenerative dis-
ease, such as neurosarcoidosis. Rheumatologic dis-
eases and infections involving the central nervous
system (CNS), e.g. human immunodeficiency virus
infection, cytomegalovirus infection or tuberculosis
would be further considerations. As, however, there
is no evidence that any of these apply to our patient,
the outstanding laboratory findings of hypokalemia
(1.5 mmol/l, normal: 3.5–5.5 mmol/l) and rhabdomy-
olysis (CK 11,788 U/l, normal: <145 U/l), should be
addressed. Typical endocrine conditions presenting
with hypokalemia and rhabdomyolysis resulting in
tetraparesis include (1) thyrotoxicosis, i.e. thyrotoxic
periodic paralysis, which is a rare clinical manifes-
tation of hyperthyroidism and presents with sudden
onset of paralysis associated with severe hypokalemia,
(2) Cushing syndrome, i.e. hypokalemia due to in-
creased renal potassium excretion caused by the
mineralocorticoid effects of cortisol and (3) massive
intake of glucocorticoids, which very rarely results in
hypokalemic paralysis.
In this hypertensive patient, hyperaldosteronism
(primary aldosteronism) should also be considered.
Primary aldosteronism is defined as inappropriately
high and (relatively or absolutely) autonomous aldos-
terone secretion, which is not adequately suppressed
by sodium loading [1]. The clinical features of pri-
mary aldosteronism are caused by hypersecretion of
aldosterone and increased activation of the mineralo-
corticoid receptor (MR) in the distal nephron. Impor-
tantly, the MR is additionally expressed in a variety of
epithelial and non-epithelial extrarenal tissues, such
as endothelial cells, vascular smoothmuscle cells, car-
diac myocytes, endothelial progenitor cells and neu-
trophils [2]. Both (1) the increased aldosterone-MR
mediated renal effects (leading to moderate sodium
and water retention and excessive potassium excre-
tion) and (2) aldosterone-MR and direct aldosterone
mediated (MR-independent and non-genomic) vas-
cular effects (contributing to e.g. vascular stiffening
and endothelial dysfunction) result in arterial hyper-
tension and, variably, hypokalemia [3–5]. Only 9–37%
of patients with primary aldosteronism present with
hypokalemia, so that it is not essential for diagnosing
aldosterone excess [6]. In severe cases of primary al-
dosteronism, hypokalemia may be expressed as mus-
cle weakness, particularly in the lower extremities,
muscle spasms, palpitations and, rarely, hypokalemic
paralysis [7], which might indeed be responsible for
our patient’s tetraparesis.
Primary aldosteronism is the most common cur-
able form of arterial hypertension and is reported in
approximately 5–10% of hypertensive patients and
in approximately 20% of those with documented
treatment-resistant hypertension [8, 9]. Our patient
is young and has a medical history of hypertension
obviously resistant to antihypertensive drugs, both
of which are important diagnostic clues for primary
aldosteronism. In primary aldosteronism, younger
hypertensive patients often respond poorly to an-
giotensin-converting enzyme inhibitors, angiotensin
receptor blockers, calcium channel blockers and beta-
blockers [10]. The use of different drugs, as in the dis-
cussed case, suggests primary aldosteronism.
Due to increased renal loss of H+ ions, alkalo-
sis is often observed in primary aldosteronism and
hypokalemia followed by secondary hyperparathy-
roidism due to the hypercalciuric effects of aldos-
terone is also a common feature of the disease. Un-
fortunately, the protocol does not include any data
on the patient’s acid-base balance and serum calcium
levels.
Taken together, severe hypokalemia and hypokale-
mic paralysis in a young patient with a medical his-
tory of treatment-resistant hypertension strongly sug-
gest the diagnosis of primary aldosteronism. As the
family history was negative for primary aldosteronism
in this case, sporadic forms, i. e. idiopathic unilat-
eral or bilateral adrenal hyperplasia and aldosterone-
producing adenomas (Conn syndrome), which is the
more severe variant of primary aldosteronism, have
to be considered. For biochemical confirmation of
the clinical suspicion of primary aldosteronism, the
aldosterone to renin ratio (ARR) would have to be de-
termined.
Dr. A. Tomaschitz’s diagnosis
Hypokalemic paralysis due to primary aldosteronism,
most likely Conn syndrome.
Discussion of case
Dr. D. Schiller: When this patient arrived in the
emergency room with tetraparesis, several differential
diagnoses were considered, including polymyositis,
acute intermittent porphyria, polyneuropathy due
to thiamine deficiency, a space-occupying lesion in
the brain, compression of the spinal cord, myasthenia
gravis, botulism and trauma. Polymyositis would have
been accompanied by characteristic dermatological
features but these were not observed. Acute inter-
mittent porphyria can sometimes lead to paralysis
but typically presents with abdominal pain, which
was not the case. Malnutrition and alcoholism can
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cause thiamine deficiency subsequently leading to en-
cephalopathy and polyneuropathy. As malnutrition
and encephalopathy were not present in our patient,
thiamine deficiency seemed unlikely to have caused
tetraparesis. MRI showed no cerebral space-occupy-
ing lesion or spinal cord compression. Guillain-Barré
syndrome could be excluded by normal cerebrospinal
fluid findings. All these neurological considerations
could be set aside after the serum potassium level of
1.5 mmol/l was reported with some delay, as the lab-
oratory staff had found the initial result implausible
and repeated the analysis.
This very low serum potassium level led to the
diagnosis of hypokalemic paralysis. Generally, hy-
pokalemia can result from increased renal or gas-
trointestinal loss or increased cellular uptake (Ta-
ble 1). Hypokalemia is often associated with QT
prolongation and the risk of ventricular tachycardia
(particularly torsades de pointes), which can be fur-
ther aggravated by the administration of drugs known
to prolong the QT interval [11]. Hypokalemia in pa-
tients with hypertension should initiate a search for
primary hyperaldosteronism. After discontinuation
of diuretics screening is performed by measuring the
plasma levels of aldosterone and renin to calculate
the ARR (Table 2). This patient’s ARR was significantly
increased (20.4, normal: <12), indicating primary al-
dosteronism. As the ARR is only a screening tool, the
definite diagnosis of primary aldosteronism has to
be confirmed by additional diagnostic tests includ-
ing suppression tests with saline, fludrocortisone and
captopril and the oral salt loading test. In the first
three tests, post-suppression serum aldosterone con-
centration is used as a diagnostic criterion; the oral
salt loading test assesses 24-h urinary aldosterone ex-
cretion [7]. With the saline suppression test, we found
a post-suppression plasma aldosterone concentration
of 55 ng/dl (cut-off value for aldosterone: >10 ng/dl),
which clearly confirmed primary aldosteronism in
our patient.
Hypersecretion in primary aldosteronism is often
caused by a single aldosterone-producing adenoma
in one adrenal gland: MRI revealed a unilateral ade-
noma, 2 cm in diameter in the left adrenal gland. This
prompted the diagnosis of classical solitary Conn ade-
noma.
Bilateral selective adrenal venous sampling (AVS,
i.e. the selective blood sampling from adrenal veins
and a peripheral site via a percutaneous femoral vein
approach and the comparison of the cortisol-cor-
rected aldosterone secretion between the two sides
using the lateralization index) is the gold standard
procedure for differentiating unilateral (surgically
curable) and bilateral adrenal disease [12]. The AVS
is a challenging procedure (particularly the cannula-
tion of the right adrenal vein) and the success rate
greatly depends on the expertise of the angiographer.
In many centers the right adrenal vein is successfully
cannulated in 50–80% of cases [13, 14]. Only a few
centers report success rates >95% [15]. Unlike the
left adrenal vein, which can be easily identified by
its drainage into the superior aspect of the left renal
vein, the right adrenal vein drains directly into the
inferior vena cava in the neighborhood of a number
of small vessels (e.g. accessory hepatic, phrenic and
retroperitoneal veins) that may look like the right
adrenal vein [16]. Moreover, the right adrenal vein is
small and short, so that catheters can easily become
dislodged during blood collection. In our patient AVS
clearly suggested a left unilateral adenoma as indi-
cated by MRI. Within 3 weeks after minimally invasive
left-sided adrenalectomy the patient’s blood pressure
decreased from 180/100 mmHg to 120/80 mmHg
and serum potassium levels returned to normal. In
30–40% of patients with Conn syndrome adrenalec-
tomy results in permanent normalization of the blood
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Fig. 1 Typical adrenocortical adenomacomposedof large
cellswith abundant foamycytoplasmanddistinct cell borders.
Note coarsenuclear chromatin, variation innuclear size and
occasional binucleatedcells but nomitotic figures (H&E, ×100)
pressure without further need of medication, as was
also the case with our patient.
Dr. C. Langner: Histologically, the adrenal gland can
be divided into the medulla, which shows a relatively
homogeneous structure and the cortex with three
concentric zones (zonae glomerulosa, fasciculata and
reticularis). Due to their different embryologic origins,
the cortex and medulla produce different hormones.
While catecholamines are synthesized in the medulla,
steroid hormones, such as mineralocorticoids, glu-
cocorticoids and sex steroids are synthesized in the
zonae glomerulosa, fasciculata and reticularis of the
cortex, respectively, with an overlap in hormones syn-
thesized by the zonae fasciculata and reticularis. Our
patient’s adenoma showed enlarged cells with pale
cytoplasm and centrally placed nuclei with marked
variation in size and there were also binucleated cells
but no mitotic figures (Fig. 1).
Dr. G.J. Krejs: In this case tetraparesis caused by se-
vere hypokalemia was the outstanding clinical feature.
Dr. Quasthoff will discuss this from the neurological
point of view.
Dr. S. Quasthoff: In patients with periodic paraly-
sis the medical history is essential for neurologists.
Exclusion of diagnoses, such as a cerebral space-oc-
cupying lesion, compression of the spinal cord and
spinal cord diseases, neuromuscular diseases, such as
myasthenia gravis, botulism, periodic paralysis due to
hyperthyroidism (i.e. thyrotoxicosis) and those dis-
cussed earlier will limit the correct neurological diag-
nosis in a patient with tetraparesis to psychogenic or
hypokalemic paralysis. With an annual incidence of
1 in 1 million inhabitants, hypokalemic tetraparesis is
seen only very rarely. Hypokalemia has different un-
derlying causes, which have to be distinguished (Ta-
ble 1). Patients with hypokalemic periodic paralysis
may experience paralytic episodes with concomitant
hypokalemia (<2.5 mmol/l) and may occasionally de-
velop late-onset proximal myopathy. The paralytic at-
tacks are characterized by reversible flaccid paralysis
usually leading to paraparesis or tetraparesis but spar-
ing the respiratory muscles and the heart [17].
The symptoms in hypokalemic paralysis can last
from minutes to hours or several days. Some in-
dividuals have only one episode in their lifetime
but more commonly, crises occur repeatedly: daily,
weekly, monthly or even less often. Events that are
associated with an increased release of epinephrine
or insulin can precipitate hypokalemic paralysis as
they cause increased movement of potassium into
cells and a subsequent decrease in serum potassium
[18, 19]. Major triggering factors are either rest after
strenuous physical activity, stress or a high carbohy-
drate load. From my personal experience I remember
two cases of hypokalemic paralysis that were both
associated with these typical triggering factors. The
first patient was a student on a summer internship
involving heavy manual labor; his daily diet was very
high in carbohydrates including up to 3 l of sugar-
sweetened beverages. This constellation finally led to
hypokalemic periodic paralysis. The second case was
a bride who presented with hypokalemic paralysis on
her wedding day. Again, stress, physical activity (in
this case dancing) and a high-carbohydrate meal were
the triggering factors. It is of interest that our patient
developed paralysis on Easter Sunday, when people
typically have a large festive meal.
When hypokalemic periodic paralysis is suspected,
the diagnosis has to be confirmed by electrophys-
iology, provocation tests and/or genetic analysis.
Detailed information on this testing is available else-
where [20]. The exercise test determines muscle
strength by electromyography after nerve stimulation.
The characteristic changes are important findings for
defining the cause of paralysis, i.e. which ion chan-
nel is affected. Alternatively, a glucose provocation
test, which aims to decrease serum potassium lev-
els to below 3 mmol/l by oral administration of 2 g
glucose/kg body weight and 10–20 IU insulin subcu-
taneously or i.v. administration of 1.5–3 g glucose/kg
body weight and insulin over a period of 60 min, can
confirm the diagnosis of hypokalemic periodic paral-
ysis. In hypokalemic paralysis, serum concentrations
of potassium are typically low (0.9–2.5 mmol/l) dur-
ing attacks but not in between. Moreover, a positive
family history is consistent with autosomal dominant
inheritance. Of all individuals meeting the diagnostic
criteria for hypokalemic periodic paralysis, approxi-
mately 60% have mutations in the calcium channel
CACNA1S gene, 20% in the sodium channel SCN4A
gene and 3.5% in the potassium KCNJ18 gene [17].
Depending on the mutation, paralysis in the affected
patients may be due to hyperkalemia or hypokalemia
(Table 3). It is important to know that in patients with
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Table 3 Clinical featuresof hypokalemic andhyperkalemicperiodicparalysis
Hypokalemic periodic paralysis Hyperkalemic periodic paralysis
Usually presents in adolescence
Attacks can be prolonged, usually occurring on awakening and accompanied
by hyporeflexia
Potassium is low during attacks
Myotonia is never present
Possible proximal myopathy
Rarely associated mild sensory axonal polyneuropathy
Electrophysiology:
Rarely associated mild sensory axonal polyneuropathy
Never myotonia
Effects of cooling unknown
Short exercise test causes no decrement
Long exercise test produces immediate increase in CMAP, especially if ini-
tial CMAP is low, followed by progressive decline in CMAP by 50% over
20–40 min with most of the decline in the first 20 min
RNS causes no decrement unless after prolonged exercise
Attacks of periodic weakness provoked by fasting, rest after exercise or cold
Attacks are brief, lasting minutes to hours and accompanied by hyporeflexia
Potassium is usually elevated during attacks
Attack relieved by ingesting carbohydrates
Development of progressive weakness during adulthood
Electrophysiology:
May not have myotonia between attacks
Rarely myopathic units
Myotonia seen early in the attack but disappears as weakness progresses
Muscle cooling has no effect
Short exercise test produces no decrement
Long exercise test produces immediate increase in CMAP, especially if ini-
tial CMAP is low, followed by progressive decline in CMAP by 50% over
20–40 min with most of the decline in the first 20 min
RNS causes no decrement unless after prolonged exercise
CMAP compound muscle action potential, RNS repetitive nerve stimulation
hypokalemic periodic paralysis, CK levels may be
increased even without myotonia, as in our patient.
Mutations in the potassium channel KCNJ2 gene
(inward-rectifier potassium ion channel) often presents
clinically as Andersen-Tawil syndrome; however, pen-
etrance is extremely variable, with some carriers of
the mutation displaying little or no phenotypic ex-
pression [21]. This rare syndrome is characterized by
a triad of episodic flaccid muscle weakness (periodic
paralysis), ventricular arrhythmia with prolonged QT
interval and skeletal anomalies [22]. Neurological pre-
sentation commonly includes episodic weakness of
skeletal muscles in a generalized pattern with sparing
of bulbar and respiratory musculature and reflexes
may be absent or diminished during the episodes
of weakness. Electrophysiological evaluation of the
nerves is of great diagnostic value, as abnormalities
are seen with sensitive testing in about 80% of cases.
Classical electrocardiographic abnormalities include
prominent Q waves, prolonged QT and QU intervals,
ventricular arrhythmias, such as premature ventricu-
lar contractions, polymorphic ventricular tachycardia
and bidirectional ventricular tachycardia. Skeletal
anomalies in the syndrome are micrognathia, ret-
rognathia, clinodactyly, syndactyly, low-set ears and
hypertelorism [23].
Table 4 provides an overview of hypokalemic and
hyperkalemic causes of paralysis, corresponding char-
acteristic symptoms, affected ion channels and treat-
ment options.
Dr. G.J. Krejs: Hypokalemia is an important diag-
nostic laboratory finding in several diseases and re-
sponsible for specific clinical features. But how often
do we actually see hypokalemia in our clinical rou-
tine? Dr. Raggam will present the experience with
potassium measurements and the frequency of hy-
pokalemia at the University Medical Center in Graz.
Dr. R.B. Raggam: From January to November 2015
a total of 349,418 serum potassium analyses were
performed at the University Medical Center in Graz.
Normal potassium levels range from 3.5 to 5.5 mmol/l;
in 0.15% (n = 531) of samples analyzed, the potassium
concentration was between 2.1 and 2.5 mmol/l and
only 0.02% (n = 85) had a concentration ≤2.0 mmol/l.
With 1.5 and 1.7 mmol/l, the lowest levels were
found in psychiatric patients. Most frequently lev-
els ≤2.0 mmol/l were seen in patients in intensive
care units and on medical and surgical wards.
For biochemical screening for primary aldostero-
nism in at-risk populations, there are no internation-
ally accepted standardized assays that are calibrated
against a standard reference substance. Calculation of
the ARR is, however, a widely accepted approach [24].
The ratio has superior test characteristics to either
plasma aldosterone concentration or plasma renin
concentration (or activity) alone [25] and it shows less
intra-day and inter-day variation. It is also less influ-
enced by preanalytical variables, such as salt intake,
diuretic exposure and posture prior to collection [26].
Calculated ARRs from different laboratories are,
however, hardly comparable because the results are
significantly influenced by (1) the assays used to
determine aldosterone and renin and (2) the pre-
vailing preconditions for blood sampling. The ARR
can be calculated from both the direct “active” renin
concentration (aldosterone to direct active renin con-
centration ratio, AARR) and the plasma renin activity
(aldosterone to renin activity ratio, ARAR). It is im-
portant to know that both parameters are different
metrics of the renin-angiotensin-aldosterone system
and will therefore show different positive screening
rates [27]. As direct active renin concentrations are
biased by various factors [7], some experts tend to
use plasma renin activity rather than renin concen-
tration to calculate the ARR [28, 29], even though
screening using the renin concentration can also be
effective [30]. The diagnostic accuracy of the ARAR is,
however, limited by conditions that affect both renin
concentrations (e.g. negative feedback inhibition
by angiotensin II) and angiotensinogen concentra-
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tions (increased during pregnancy, glucocorticoid
excess and estrogen administration; decreased in
liver disease) [31]. In contrast, the advantages of
ARAR over AARR may be a better low-end precision
and a more complete assessment of the renin-an-
giotensin-aldosterone system tone [7]. Glinicki et al.
recently suggested a similar diagnostic accuracy of
the ARAR and AARR [32]. In summary, for practical
and economic reasons ARAR can be replaced by the
aldosterone to direct active renin concentration ratio
(AARR). Due to these analytical complexities, the ARR
should always be interpreted in the context of the
full clinical picture including medical and family his-
tory of early cardiovascular events, of early onset of
arterial hypertension, severity of hypertension, resis-
tance to antihypertensive drugs, presence of adrenal
adenoma, absolute aldosterone concentration, the
presence of electrolyte abnormalities and responsive-
ness to aldosterone antagonists [7]. When screening
is positive, a confirmatory aldosterone suppression
test must be performed to definitely diagnose primary
aldosteronism.
Dr. G.J. Krejs: At the University Medical Center of
Graz only 1 out of approximately 350,000 measure-
ments per year yields a serum potassium level as
low as 1.5 mmol/l as observed in our patient. In
the past 45 years of my medical career I have just
once seen a patient with a potassium level as low
as 1.5 mmol/l. That patient suffered from Verner-
Morrison syndrome, i.e. watery diarrhea hypokalemia
hypochlorhydria (WDHH) syndrome, also known as
VIPoma (vasoactive intestinal peptide) or pancreatic
cholera [33] and experienced hypokalemic paralysis
caused by massive gastrointestinal potassium loss. He
was paralyzed to such a degree that he could not lift
the telephone receiver to call for help.
The prevalence of hypertension has increased over
the past decades and currently affects about 1 billion
people worldwide [34]. Although most cases of hy-
pertension are “essential” or “idiopathic,” some cases
have an identifiable cause, representing secondary hy-
pertension for which curative therapy can be offered.
The most common form of secondary hypertension
is primary aldosteronism [5]. Primary aldosteronism
was first described in 1955 by Conn at Yale Univer-
sity, who reported a 34-year-old woman with hy-
pertension, intermittent paralysis, hypokalemia and
metabolic alkalosis [35]. The patient further showed
increased activity of urinary salt-retaining corticoid
and was cured by removal of a benign adrenal ade-
noma [36]. Initially Conn suggested that about 20%
of hypertensive patients might be affected by pri-
mary aldosteronism but later revised his estimate to
10% [37]. Currently it is suggested that in 5–13%
of patients with hypertension the cause is primary
aldosteronism with higher rates in younger hyper-
tensive patients [5, 7]. Dr. Pilz is an endocrinologist
and will present some important facts on primary
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Table 5 Subtypesof pri-
maryaldosteronismand
their frequency [5, 7, 38]
Subtype Relative frequency (%)
Sporadic forms
Idiopathic adrenal hyperplasia 60–65
Aldosterone-producing adenoma (Conn syndrome) 30
Primary unilateral adrenal hyperplasia 2–3
Aldosterone-producing adrenocortical carcinoma 1
Aldosterone-producing ovarian tumor <1
Familial forms
Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism) caused by
a fusion gene between CYP11B2 (aldosterone synthase) and CYP11B1 (11-ß-hydroxy-
lase) resulting in excessive aldosterone production in response to adrenocorticotropin
[39]
<1
Familial hyperaldosteronism type II (familial occurrence of aldosterone-producing ade-
noma or bilateral idiopathic hyperplasia or both; genetic cause is under investigation)
Unknown
Familial hyperaldosteronism type III (non-glucocorticoid-remediable hyperaldostero-
nism) caused by mutations of the inward rectifier potassium channel 4 (GIRK4) which is
encoded by the KCNJ5 gene [40, 41]
Unknown
Ectopic aldosterone-producing adenoma or carcinoma <0.1
aldosteronism and tell us about experiences with this
disease at the University Medical Center of Graz.
Dr. S. Pilz: Primary aldosteronism is characterized
by aldosterone concentrations that are inappropri-
ately high in relation to renin and that are not ade-
quately suppressible by sodium loading, which would
normally reduce aldosterone secretion [7]. Identifica-
tion of primary aldosteronism and its specific forms
(Table 5) is essential because affected patients have
higher cardiovascular morbidity and mortality than
age, sex and blood pressure-matched patients with
essential hypertension [10, 42]. High aldosterone
levels have adverse cardiovascular effects that are in-
dependent of hypertension and include endothelial
dysfunction, left ventricular hypertrophy and fibrosis
of the kidney, heart and blood vessels [43]. Early
detection of primary aldosteronism by screening of
hypertensive patients is important because it will
allow targeted and effective treatment and will so
reduce the excess cardiovascular risk [44, 45].
According to the Endocrine Society clinical prac-
tice guidelines, testing for primary aldosteronism
should be considered in any of the following cir-
cumstances: (1) sustained blood pressure above
150/100 mmHg on each of three measurements ob-
tained on different days, (2) hypertension (blood pres-
sure >140/90 mmHg) resistant to three conventional
antihypertensive drugs (including a diuretic), (3) con-
trolled blood pressure (<140/90 mmHg) on four or
more antihypertensive drugs, (4) arterial hypertension
and spontaneous or diuretic-induced hypokalemia,
(5) hypertension and adrenal incidentaloma, (6) hy-
pertension and sleep apnea, (7) hypertension and
a family history of early onset hypertension or cere-
brovascular accident at a young age (<40 years) and
(8) all hypertensive first-degree relatives of patients
with primary aldosteronism [12]. As already described
by Drs. Schiller and Raggam, primary aldosteronism
is usually diagnosed by measuring plasma aldos-
terone and direct active renin concentrations or renin
activity and calculating the ARAR or AARR. If ARAR
or AARR is elevated, confirmatory aldosterone sup-
pression should usually be conducted to verify au-
tonomous aldosterone production and thus confirm
the diagnosis of primary aldosteronism. When test-
ing for primary aldosteronism it is recommended to
withdraw mineralocorticoid receptor antagonists (e.g.
spironolactone and eplerenone) and amiloride and
triamterene for at least 4 weeks before blood sam-
pling to avoid spurious results. Potassium should also
be normalized before testing because hypokalemia
strongly suppresses aldosterone secretion. If a young
patient (<35 years) has marked aldosterone excess and
spontaneous hypokalemia along with plasma renin
levels below detection levels there may be no need
for further confirmation testing [5]. Beyond these
diagnostic procedures for primary aldosteronism, it
should be emphasized that one important differential
diagnosis for patients with profound hypokalemia
and hypertension is ectopic, i.e. adrenocorticotropic
hormone dependent Cushing syndrome that is usu-
ally accompanied by significant metabolic alkalosis
and very rapid disease progression requiring early di-
agnosis and treatment [46]. Some drugs such as beta-
adrenergic blockers, angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers may also
impact on the ARR and it is desirable to withdraw
these drugs for at least 4 weeks before testing.
In addition to renin (activity) and aldosterone lev-
els for calculation of ARR or AARR, analysis of parathy-
roid hormonemay be of additional diagnostic value in
primary aldosteronism. Patients with significant pri-
mary aldosteronism frequently present with elevated
parathyroid hormone levels that may be due to in-
creased renal and fecal calcium loss, metabolic alka-
losis or direct effects on the parathyroid glands medi-
ated by aldosterone [47].
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The overall prevalence of primary aldosteronism,
which of course greatly depends on the diagnostic
criteria applied (e.g. ARR cut-offs), is relatively low
at our center; according to the Graz endocrine causes
of hypertension (GECOH) study approximately 3–5%
of patients referred for screening for endocrine hy-
pertension are diagnosed with primary aldosteronism
per year at the University Medical Center in Graz [48,
49]. In absolute numbers this means 5 patients are
diagnosed here per year; however, appropriate and
targeted screening of suspicious patients is pivotal for
early diagnosis and adequate therapy.
Dr. G.J. Krejs: In summary, this interesting case
showed that primary aldosteronism due to an aldos-
terone-producing adenoma (Conn syndrome) led to
severe hypokalemic paralysis. Primary aldosteronism
is not often seen in the daily routine but is detected in
about five patients per year at our medical center and
hypokalemic paralysis is seen even less often. Early
identification of patients with primary aldosteronism
and the correct subtype is important for the choice of
the best therapy. In the discussed patient minimally
invasive adrenalectomy was curative.
Dr. A. Tomaschitz: As a final comment on this case:
hypokalemic tetraparesis in primary aldosteronism is
rare but physicians should nevertheless be aware of
this clinical feature. Regarding primary aldosteronism
it is important to know that hypokalemia is only found
in 37% of patients with primary aldosteronism and
that hypokalemia is more common when the disease
has progressed [6, 50]. As potassium levels are often
within the normal range, hypokalemia is an insensi-
tive diagnostic tool for primary aldosteronism. The
ARR or AARR are the acceptable approaches for de-
tecting primary aldosteronism but a confirmatory al-
dosterone suppression test must be performed before
treatment can be initiated.
Final diagnosis
Hypokalemic paralysis due to primary aldosteronism
(Conn syndrome).
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